You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

WAINUA (AUTOINJECTOR) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Wainua (autoinjector), and what generic alternatives are available?

Wainua (autoinjector) is a drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this drug.

This drug has two hundred and twenty-nine patent family members in thirty-five countries.

The generic ingredient in WAINUA (AUTOINJECTOR) is eplontersen sodium. One supplier is listed for this compound. Additional details are available on the eplontersen sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Wainua (autoinjector)

Wainua (autoinjector) will be eligible for patent challenges on December 21, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for WAINUA (AUTOINJECTOR)?
  • What are the global sales for WAINUA (AUTOINJECTOR)?
  • What is Average Wholesale Price for WAINUA (AUTOINJECTOR)?
Summary for WAINUA (AUTOINJECTOR)
International Patents:229
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:WAINUA (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for WAINUA (AUTOINJECTOR)

US Patents and Regulatory Information for WAINUA (AUTOINJECTOR)

WAINUA (AUTOINJECTOR) is protected by four US patents and two FDA Regulatory Exclusivities.

Patents protecting WAINUA (AUTOINJECTOR)

Compositions and methods for modulating TTR expression
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

Modulation of transthyretin expression
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conjugated antisense compounds and their use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conjugated antisense compounds and their use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting WAINUA (AUTOINJECTOR)

TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
Exclusivity Expiration: ⤷  Sign Up

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for WAINUA (AUTOINJECTOR)

See the table below for patents covering WAINUA (AUTOINJECTOR) around the world.

Country Patent Number Title Estimated Expiration
Japan 6866459 ⤷  Sign Up
South Korea 102315836 ⤷  Sign Up
South Korea 20200090966 아포지질단백질 C-III 발현을 조절하는 조성물 및 방법 (C-III COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION) ⤷  Sign Up
Japan 6387084 ⤷  Sign Up
Morocco 46019 Compositions et méthodes pour moduler l'expression de hbv et de ttr ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.